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Received January 21, 2015; accepted September 16, 2015AbstractBackground: The number of studies on adiponectin, GPx-1 gene polymorphisms, and nonalcoholic fatty liver disease (NAFLD) susceptibility is
increasing, but none have investigated the effect of cigarette smoking in combination with the gene polymorphisms on the susceptibility to
NAFLD. In order to understand the distribution of adiponectin and GPx-1 in the local population, to explore the possible association of cigarette
smoking with adiponectin and GPx-1 gene polymorphisms in the pathogenesis of NAFLD, we conducted this research, examining the distri-
bution of polymorphisms of adiponectin and GPx-1 in NAFLD patients and healthy controls, analyzing the association between these poly-
morphisms and cigarette smoking.
Methods: Two hundred nonalcoholic simple fatty liver (NAFL), 200 nonalcoholic steatohepatitis (NASH), and 200 nonalcoholic fatty hepatic
cirrhosis (NAFHC) cases from the First Affiliated Hospital of Xinxiang Medical College in China from February 2011 to November 2014 were
selected for this study, and 200 healthy individuals as a control group. No significant difference among the four groups in age, sex, ethnicity, and
birthplace was observed. The genetic polymorphisms of adiponectin gene promoter-11377C/G and GPx-1 gene C594T were analyzed using
polymerase chain reaction-restriction fragment length polymorphisms in peripheral blood leukocytes of the above-mentioned cases. The
interaction between the two mutants and the gene-environment association of the genotypes with cigarette smoking were analyzed.
Results: The frequencies of adiponectin gene promoter-11377C/G(CG), -11377C/G (GG), GPx-1 gene C594T (CT) and C594T (TT) were
24.50%, 26.00%, 24.00%, and 25.50% in the NAFL group, 34.50%, 37.00%, 35.00%, and 36.00% in the NASH group, 42.00%, 46.00%,
43.50%, and 45.50% in the NAFHC group, and 14.00%, 14.50%, 13.00%, and 14.00% in the control group, respectively. Statistical tests showed
a significant difference in the frequencies among each group ( p < 0.01). The risk of NAFLD significantly increased in patients with adiponectin
gene promoter-11377C/G (CG) genotype [odds ratio (OR)NAFL ¼ 2.5278; ORNASH ¼ 6.1823; ORNAFHC ¼ 17.8570), in those with -11377C/G
(GG) genotype (ORNAFL ¼ 2.5900; ORNASH ¼ 6.4017; ORNAFHC ¼ 18.9023), in those with GPx-1 gene C594T (CT) genotype
(ORNAFL ¼ 2.6687; ORNASH ¼ 6.7772; ORNAFHC ¼ 22.2063), and in those with C594T (TT) genotype (ORNAFL ¼ 2.6330; ORNASH ¼ 6.4729;
ORNAFHC ¼ 21.5682). Combined analysis of the polymorphisms showed that percentages of adiponectin gene promoter -11377C/G (GG)/GPx-1
gene C594T (TT) in the NAFL, the NASH, NAFHC, and control groups was 7.00%, 13.50%, 21.00%, and 2.00%, respectively ( p < 0.01). The
people who carried the adiponectin gene promoter -11377C/G (GG)/GPx-1 gene C594T (TT) had a high risk of NAFLD (ORNAFL ¼ 7.2800;
ORNASH ¼ 41.2941; ORNAFHC ¼ 363.9724), and statistical analysis suggested a positive association between -11377C/G (GG) and C594T (TT)
in increasing the risk of NAFLD (g2NAFL ¼ 2.2071, g4 NAFL ¼ 2.0773; g2 NASH ¼ 2.1084; g4NASH ¼ 2.0543; g2 NAFHC ¼ 2.1387;
g4NAFHC ¼ 2.0004). Likewise, there were also positive association in the pathogenesis of NAFLD between -11377C/G (CG) and C594T (TT),
-11377C/G (CG) and C594T (CT), -11377C/G (GG), and C594T (TT) (CT).The frequencies of smoking index (SI)  400 and SI > 400 were
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196 C.-X. Zhang et al. / Journal of the Chinese Medical Association 79 (2016) 195e20412.00% in the control group, respectively. Statistical tests showed a significant difference in the frequencies among each group (all p < 0.01).
The risk of NAFLD significantly increased in patients with SI  400 (ORNAFL ¼ 2.0636; ORNASH ¼ 4.4474; ORNAFH C ¼ 10.9677) and in those
with SI > 400 (ORNAFL ¼ 3.1393; ORNASH ¼ 8.0225; ORNAFHC ¼ 21.4583), and statistical analysis suggested a positive association between
cigarette smoking and -11377C/G (CG), -11377C/G (GG), C594T (CT), and C594T (TT) in increasing the risk of NAFLD (all g > 1).
Conclusion: Adiponectin gene promoter -11377C/G (CG), -11377C/G (GG), GPx-1 gene C594T (CT), C594T (TT), and cigarette smoking are
risk factors in NAFLD, and the significant association between genetic polymorphisms of -11377C/G, C594T, and cigarette smoking amplify the
risk of NAFLD.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The exact mechanism of nonalcoholic fatty liver disease
(NAFLD) is unclear, but the two-hit theory is more popular
than other hypotheses. The theory states that insulin resistance
can cause liver fat accumulation in hepatocytes, the first hit in
the pathogenesis of NAFLD, which makes the liver more
vulnerable to oxidative stress and subsequent lipid peroxida-
tion, among the factors constituting the second hit, thus pro-
gressing to inflammation and fibrosis, and eventually
NAFLD.1,2
Cigarettes release nicotine and carbon monoxide in the
combustion process. These ingredients interfere with lipid
metabolism, and multiple ingredients of cigarettes also stim-
ulate and promote free radical lipid peroxidation, which par-
ticipates in the development of NAFLD.3 Adiponectin, one of
the major adipocyte-secreted proteins, has attracted scientific
interest in recent years and has been extensively studied in
both human and animal models. Adiponectin exerts insulin-
sensitizing effects through binding to adiponectin receptors,
leading to activation of adenosine monophosphate-activated
protein kinase, peroxisome proliferators activated receptor-a,
and potentially other unknown molecular pathways. The role
of adiponectin in improving insulin sensitivity is such that it
has become an important factor in inhibiting the progress of
NAFLD.4 Glutathione peroxidase-1 (GPx-1) has the function
of scavenging free radicals and derivatives, and phospholipid
hydroperoxide glutathione peroxidase constitutes with catalase
and glutathione-S-transferase (an organic hydroperoxide
reduction system) at different levels of substrate specificity,
reducing the formation of lipid peroxides and enhancing
resistance to oxidation damage, an important factor that con-
trols the progression of NAFLD.5 Adiponectin and GPx-1
genes have polymorphisms which have multiple alleles with
different alleles encoding different adiponectin or GPx-1 ac-
tivities. Polymorphisms in adiponectin or GPx-1 genes can
affect the reaction of the body to the external environment
(such as smoking), which is an important factor that de-
termines its susceptibility to NAFLD.
The number of studies on adiponectin, GPx-1 gene poly-
morphisms, and NAFLD susceptibility is increasing, but none
have investigated the effect of cigarette smoking in combi-
nation with the gene polymorphisms on the susceptibility toNAFLD. In order to understand the distribution of adiponectin
and GPx-1 in the local population, to explore the possible
association of cigarette smoking with adiponectin and GPx-1
gene polymorphisms in the pathogenesis of NAFLD, we
conducted this research examining the distribution of poly-
morphisms of adiponectin and GPx-1 in NAFLD patients and
healthy controls, and analyzed the relationship between these
polymorphisms and smoking status.
2. Methods2.1. Diagnostic criteriaThe diagnosis of NAFLD was based on guidelines for
diagnosis and treatment of NAFLD revised by the Fatty Liver
and Alcoholic Liver Disease Study Group of the Chinese Liver
Disease Association in 2010.62.2. Inclusion criteria(1) The patients conformed to the above diagnostic criteria of
NAFLD; (2) the patients were aged from 17 years to
69 years, men or women; (3) alanine transaminase or
aspartate transaminase level was less than 80 U/L; (4) the
patients voluntarily signed an informed consent form and
passed ethic evaluation.2.3. Exclusion criteria(1) History of alcohol intake > 20g/d; (2) co-existence of
other liver diseases, such as viral, drug-induced, auto-im-
mune hepatitis, and so on; (3) suspicion of liver cirrhosis
or liver cancer; (4) co-existence of other severe systematic
disease or infectious disease, such as malignant neoplasm,
severe cardiopulmonary disease, neurological disorders,
human immunodeficiency virus infection, and so on; (5)
currently pregnant, breastfeeding, pregnancy anticipated
during study, or planning to conceive; (6) co-existence of
mental disorders or severe neurosis, or unable to express
symptoms subjectively, and hindering of connection and
cooperation with researchers because of dysgnosia or
aphasis.
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Fig. 1. The electrophoretogram of PCR products indicating the -11377 variants
of adiponectin gene promoter.Based on the above-mentioned diagnostic, inclusion, and
exclusion criteria, 200 nonalcoholic simple fatty liver (NAFL),
200 nonalcoholic steatohepatitis (NASH), and 200 nonalco-
holic fatty hepatic cirrhosis (NAFHC) cases were selected for
this study from the Department of Gastroenterology of the
First Affiliated Hospital of Xinxiang Medical University from
February 2011 to November 2014. The control group con-
sisted of 200 healthy people, excluding persons with type 2
diabetes, obesity, hypertension, hyperlipidemia, and other
metabolic disorders, as well as those with a history of drink-
ing. There was no significant difference between the four
groups in age, sex, ethnicity, and birthplace. The NAFLD
cases and healthy controls were all divided into nonsmokers
and smokers, the latter identified based on the criteria of
taking at least one cigarette per day for more than 6 months.
Smoking status was estimated by smoking index (SI) ¼ daily
cigarette consumption (piece)  duration of cigarette smoking
(year). According to SI value, the smokers were divided into
SI  400 and SI > 400 subgroups.2.5. Sample collectionBlood samples (2e3 mL) were collected into ethyl-
enediaminetetraacetic acid tubes containing an anticoagulant.
After centrifugation, three blood fractions were obtained:
plasma, red blood cells, and a buffy layer containing white
blood cells. DNA was extracted from the white blood cells
using the QIAamp DNA extraction kit (Qiagen, Hilden, Ger-
many) and stored at 30C for the following experiments.2.6. Analysis of polymorphisms of adiponectin gene
promoter-11377C/GThe analysis of -11377C/G polymorphism was conducted
by reference to the method of Gupta et al.7 The primer se-
quences were: 50-TGGTGGACTTGACTTTACTG-30 (up-
stream primer) and 50-CAGCCTG GAGAACTGGAA-30
(downstream primer), both synthesized by Shanghai Sangon
Biological Engineering Technology & Services Co., Ltd. The
polymerase chain reaction (PCR) reaction system included:
1 mL of genomic DNA, 0.5 mL of upstream and downstream
primers, 25 mL of Taq DNA polymerase Mix (Dalian Takara
Biotechnology Co., Ltd, Liaoning Province, China). The re-
action conditions were: predegeneration at 94C for 5 mi-
nutes; 94C degeneration for 40 seconds, and annealing at
55C 45 seconds, 72C for 30 seconds, 40 cycles; the last
extension at 72C for 7 minutes. The length of PCR products
was 329 bp. Bio-Rad staining of agarose gel electrophoresis
confirmed the amplification results. The PCR products were
digested with restriction endonuclease Hha I. The enzyme
digestion products were observed with ultraviolet gel imager,
in which three genotypes were visible: homozygous CC
(329 bp band), homozygous GG (211 and 118 bp bands), and
heterozygote CG (329 bp, 211 bp, and 118 bp bands Fig. 1).2.7. Analysis of GPx-1 gene C594T polymorphismThe analysis of GPx-1 gene C594T polymorphism was
conducted by reference to the method of Suzen et al.8 The
primer sequences were: 50-CCTACGCAGGTACAGCC-30
(upstream primer), 50-CAACAGGACCAGCACCCATCTC-30
(downstream primer), synthesized by Shanghai Sangon Bio-
logical Engineering Technology & Services Co., Ltd.
Application of TaKaRa PCR amplification kit (Dalian Takara
Biotechnology Co.) PCR was conducted in 25 mL reactions,
containing 1-mL template DNA, 2.5 mL10  PCR buffer, 2 L
deoxynucleotide mixture, 0.125 mL TaKaRa Taq DNA poly-
merase, 15pmol primers, and 17.375-mL sterilized deionized
water. The PCR reaction conditions were as follows: pre-
degeneration at 93C for 3 minutes; 93C degeneration for
1 minute, annealing at 66C for 1 minute, at 70C for
1 minute, 35 cycles; and extension at 70C for 10 minutes.
The length of PCR product was 240 bp. PCR reaction
products (12 mL) were incubated with restriction endonu-
clease Dde at 37C in a water bath. Enzyme-digested prod-
ucts were analyzed with 3.5% agarose gel electrophoresis
(containing 0.5 mg/mL ethidium bromide). The electropho-
retogram showed homozygous C594T (CC) (240 bp band),
homozygous C594T (TT) (163 bp and 77 bp bands), and
heterozygous C594T (CT) (240 bp, 163 bp, and 77 bp bands;
Fig. 2).2.8. Statistical analysisSPSS statistical package for Windows 11.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analysis. Groups
were tested to determine whether they were in HardyeWein-
berg equilibrium, with p > 0.05 indicating compliance with
HardyeWeinberg law. The odds ratio (OR) and 95% confi-
dence interval were used to evaluate the relative risk between
the NAFLD group and the control group, with the gene fre-
quency and allele frequency analyzed using c2 test. A p
value < 0.05 was considered statistically significant.
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Fig. 2. The electrophoretogram of PCR products indicating the glutathione
peroxidase-1 gene C594T polymorphism.
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action, with the following criteria according to the model of
interaction and interaction coefficients of Khoury and Wage-
ner (g ¼ beg/be) in determining geneeenvironment interac-
tion.9 Criteria 1 were: g >1 indicates that the effect of
environmental exposure was amplified by genetic factors, i.e.,
positive interaction; g < 1 indicates that the effect of envi-
ronmental exposure was reduced by genetic factors, i.e.,
negative interaction; g ¼ 1 indicates that gene and environ-
mental exposure had no interaction. In a case-control study, g
equaled to lgOReg divided by lgORe. Criteria 2 were:
OReg ¼ ORe  ORg is a multiplicative model;
OReg > ORe  ORg is a super-multiplicative model;
OReg < ORe  ORg for the multiplicative model;
OReg ¼ ORe þ ORg  1 is an additive model.Table 1
General information of the nonalcoholic fatty liver disease and control groups [n
Items Control group
NAFL group p
Sex, n (%) 0.1905
Male 120 (60.00) 121 (60.50)
Female 80 (40.00) 79 (39.50)
Age (y) 54.71 ± 4.89 54.72 ± 5.73 0.2318
BMI (kg/m2) 48.47 ± 14.57 55.87 ± 4.29 0.0094
WC (cm) 73.06 ± 7.05 84.46 ± 9.57 0.0071
HC (cm) 76.91 ± 15.11 84.75 ± 11.23 0.0091
WHR 0.77 ± 0.09 0.87 ± 0.04 0.0082
SBP (mmHg) 123.89 ± 15.81 137.35 ± 16.39 0.0072
DBP (mmHg) 74.16 ± 10.37 85.57 ± 16.08 0.0096
FBG (mmol/L) 5.54 ± 1.29 6.42 ± 1.54 0.0077
AST (U/L) 24.36 ± 11.28 35.63 ± 13.71 0.0083
ALT (U/L) 18.50 ± 9.63 30.51 ± 1214 0.0085
TG (mmol/L) 1.25 ± 0.47 1.97 ± 1.01 0.0095
TC (mmol/L) 4.29 ± 1.87 5.34 ± 1.62 0.0087
LDL-C (mmol/L) 2.40 ± 1.51 2.97 ± 1.39 0.0084
HDL-C (mmol/L) 1.93 ± 0.84 1.52 ± 0.47 0.0063
FINS (mIU/L) 6.38 ± 2.18 8.65 ± 3.94 0.0072
hs-CRP (mg/L) 2.36 ± 0.52 2.94 ± 1.05 0.0081
ALT ¼ alanine transaminase; AST ¼ aspartate transaminase; BMI ¼ body ma
FINS ¼ fasting serum insulin; HC ¼ hip circumference; HDL-C ¼ high-density
C ¼ low density lipoprotein cholesterol; NAFL ¼ nonalcoholic simple fatty liver;
liver disease; NASH ¼ nonalcoholic steatohepatitis; SBP ¼ systolic blood pressure;
WHR ¼ waist-to-hip ratio..3. Results3.1. General information of NAFLD group and control
groupThere was no significant difference among each group in
age and sex. The body mass index, waist circumference, hip
circumference, waist-to-hip ratio, systolic blood pressure,
diastolic blood pressure, fasting blood glucose, aspartate
transaminase, alanine transaminase, triglyceride, serum total
cholesterol, low density lipoprotein cholesterol, fasting serum
insulin, and high sensitivity C-reactive protein in the NAFL,
NASH, and NAFHC groups were all significantly higher than
that in the control group ( p < 0.01), while high-density li-
poprotein cholesterol was significantly lower than that in the
control group ( p < 0.01; Table 1).3.2. Related analysis of NAFLD susceptibility and
smokingThe frequencies of SI  400 and SI > 400 were 22.50%
and 26.50% in NAFL cases, 29.00% and 40.50% in NASH
cases, 34.00% and 51.50% in NAFHC cases, and 15.50% and
12.00% in healthy controls, respectively. Statistical tests
showed significant difference in the frequencies among each
group (all p < 0.01). The risk of NAFLD significantly
increased in subjects with SI  400 (ORNAFL ¼ 2.0636;
ORNASH ¼ 4.4474; ORNAFHC ¼ 10.9677) and in those with
SI > 400 (ORNAFL ¼ 3.1393; ORNASH ¼ 8.0225;
ORNAFHC ¼ 21.4583). The NAFLD incidence of SI > 400 was
significantly higher than that of SI  400 ( p < 0.01; Table 2).(%)].
NAFLD group
NASH group p NAFHC group p
0.2147 0.1932
119 (59.50) 117 (58.50)
81 (40.50) 83 (41.50)
54.63 ± 9.25 0.2842 54.91 ± 4.53 0.1726
65.51 ± 11.35 0.0082 76.39 ± 10.71 0.0073
95.52 ± 9.79 0.0063 103.84 ± 12.81 0.0057
98.40 ± 13.61 0.0076 112.52 ± 17.75 0.0052
0.93 ± 0.03 0.0075 1.05 ± 0.12 0.0065
148.46 ± 22.37 0.0058 158.16 ± 12.81 0.0049
95.67 ± 26.14 0.0085 1125.38 ± 26.52 0.0079
7.82 ± 1.97 0.0056 7.82 ± 1.97 0.0046
47.63 ± 15.86 0.0062 59.39 ± 18.24 0.0051
37.91 ± 17.07 0.0068 53.91 ± 13.62 0.0048
2.58 ± 1.38 0.0075 3.82 ± 1.56 0.0042
6.64 ± 2.61 0.0072 7.51 ± 3.68 0.0059
3.27 ± 1.14 0.0061 3.27 ± 1.14 0.0032
1.35 ± 0.56 0.0047 1.03 ± 0.27 0.031
12.65 ± 3.17 0.0059 15.47 ± 6.98 0.0025
3.85 ± 1.21 0.0047 3.85 ± 1.21 0.0039
ss index; DBP ¼ diastolic blood pressure; FBG ¼ fasting blood glucose;
lipoprotein cholesterol; hs-CRP ¼ high sensitivity C-reactive protein; LDL-
NAFHC ¼ non-alcoholic fatty hepatic cirrhosis; NAFLD ¼ nonalcoholic fatty
TC ¼ serum total cholesterol; TG ¼ triglyceride; WC ¼ waist circumference;
Table 2
Related analysis of nonalcoholic fatty liver disease susceptibility and smoking.
Groups Smoking status, n (%)
Nonsmoking SI  400 SI > 400
Control group (n ¼ 200) 145 (72.50) 31 (15.50) 24 (12.00)
NAFL group (n ¼ 200) 102 (51.00) 45(22.50) 53 (26.50)
ORa NAFL 1.00 2.0636 3.1393
95% CI NAFL 1.2317e5.2186 1.9354e5.2175
p NAFL 0.0092 0.0089
NASH group (n ¼ 200) 61 (30.50) 58 (29.00) 81 (40.50)
ORa NASH 1.00 4.4474* 8.0225*
95% CI NASH 2.5081e7.2194 4.4763e11.2165
p NASH 0.0085 0.0072
NAFHC group (n ¼ 200) 29 (14.50) 68 (34.00) 103 (51.50)
ORa NAFHC 1.00 10.96771*
,** 21.4583*,**
95% CI NAFHC 6.2647e14.3210 16.2627e32.3215
pNAFHC 0.0063 0.0047
* Compared with ORa NAFL, p < 0.01.
** Compared with ORa NASH, p < 0.01.
CI ¼ confidence interval; NAFHC ¼ nonalcoholic fatty hepatic cirrhosis;
NAFL ¼ nonalcoholic simple fatty liver; NASG ¼ nonalcoholic steatohepa-
titis; OR ¼ odds ratio; SI ¼ smoking index.
a Adjusted according to sex, age, body mass index, waist circumference, hip
circumference, waist-to-hip ratio, systolic blood pressure, diastolic blood
pressure, fasting blood glucose, aspartate transaminase, alanine transaminase,
triglyceride, total cholesterol, low density lipoprotein cholesterol, fasting
serum insulin, and high sensitivity C-reactive protein.
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promoter-11377C/G and GPx-1 gene C594T
polymorphismThe genotype distribution of -11377C/G in the control
group complied with the HardyeWeinberg law ( p > 0.05),
indicating representativeness of this group (Table 3). There
was a significant difference among each group in CC, CG, andTable 3
Distribution of polymorphisms of adiponectin gene promoter-11377C/G genotypes
Groups Genotype, n (%)
CC CG
Control (n ¼ 200) 143 (71.50) 28 (14.00)
NAFL (n ¼ 200) 99 (49.50) 49 (24.50)
ORa NAFL 1.00 2.5278
95% CI NAFL 1.6347e4.2191
p NAFL 0.0089
NASH (n ¼ 200) 57 (28.50) 69 (34.50)
ORa NASH 1.00 6.1823*
95% CI NASH 3.1762e9.3258
p NASH 0.0079
NAFHC(n ¼ 200) 24 (12.00) 84 (42.00)
ORa NAFHC 1.00 17.8750*
,**
95% CI NAFHC 9.3769e25.4301
p NAFHC 0.0052
* Compared with ORa NAFL, p < 0.01.
** Compared with ORa NASH, p < 0.01.
CI ¼ confidence interval; NAFHC ¼ nonalcoholic fatty hepatic cirrhosis; NAF
OR ¼ odds ratio; SI ¼ smoking index.
a Adjusted according to sex, age, body mass index, waist circumference, hip circ
fasting blood glucose, aspartate transaminase, alanine transaminase, triglyceride, to
high sensitivity C-reactive protein, and smoking status.GG genotype frequency ( p < 0.01), and in the distribution of
G allele ( p < 0.01), the OR value was greater than 1, the risk
of NAFLD with the allele G was significantly higher than the
allele C. C594T genotype, and allele frequency is in accor-
dance with the above rules (Table 4).3.4. Interaction of the two polymorphisms in NAFLDThe percentages of -11377C/G (GG) C594T (TT) in NAFL,
NASH, NAFHC, and control groups were 7.00%, 13.50%,
21.00%, and 2.00%, respectively ( p < 0.01). The people who
carried with -11377C/G (GG)/C594T (TT) had a high risk of
NAFLD (ORNAFL ¼ 7.2800; ORNASH ¼ 41.2941;
ORNAFHC ¼ 363.9724), and statistical analysis suggested a
positive interaction between -11377C/G (GG) and C594T (TT)
in increasing the risk of NAFLD(g2 ¼ b2*4/b4, g4 ¼ b2*4/b2;
g2NAFL ¼ 2.2071, g4NAFL ¼ 2.0773; g2 NASH ¼ 2.1084,
g4NASH ¼ 2.0543; g2 NAFHC ¼ 2.1387,g4NAFHC ¼ 2.0004).
Likewise, there were also positive associations in the patho-
genesis of NAFLD between -11377C/G (CG) and C594T
(TT), -11377C/G (CG) and C594T (CT), -11377C/G (GG),
and C594T (CT) (Table 5).3.5. Interaction of the two polymorphisms with cigarette
smoking in NAFLDThe OR value by simple SI  400 exposure (ORe1) was
2.2189 in the NAFL group, 4.7273 in the NASH group, and
12.6061 in the NAFHC group, the OR value by simple
-11377C/G (CG) exposure (ORg1) was 2.5267 in the NAFL
group, 6.1176 in the NASH group, and 19.8095 in the NAFHC
group, when SI  400 and -11377C/G (CG) existed simulta-
neously, the interaction ORe1g1 was 5.8367 in the NAFL
group, 30.5882 in the NASH group, and 251.3332 in theand allele.
Allele, n (%)
GG C G
29 (14.50) 314 (78.50) 86 (21.50)
52 (26.00) 247 (61.75) 153 (38.25)
2.5900 1.00 2.2617
1.7380e4.7036 1.2041e3.8664
0.0085 0.0097
74 (37.00) 183 (45.75) 217 (54.25)
6.4017* 1.00 4.3295*
3.4726e9.8042 2.3790e7.9782
0.0072 0.0086
92 (46.00) 132 (33.00) 268 (67.00)
18.9023*,** 1.00 7.4130*,**
11.3714e26.30852 4.3017e10.1854
0.0049 0.0074
L ¼ nonalcoholic simple fatty liver; NASG ¼ nonalcoholic steatohepatitis;
umference, waist-to-hip ratio, systolic blood pressure, diastolic blood pressure,
tal cholesterol, low density lipoprotein cholesterol, fasting serum insulin, and
Table 4
Distribution of GPx-1 gene C594T polymorphism genotypes and allele.
Groups Genotype, n (%) Allele, n (%)
CC CT TT C T
Control (n ¼ 200) 146 (73.00) 26 (13.00) 28 (14.00) 318 (79.50) 82 (20.50)
NAFL (n ¼ 200) 101 (50.50) 48 (24.00) 51 (25.50) 250 (62.50) 150 (37.50)
ORa NAFL 1.00 2.6687 2.6330 1.00 2.3268
95% CI NAFL 1.5342e4.6813 1.5107e4.7136 1.3153e3.8719
p NAFL 0.0087 0.0091 0.0094
NASH (n ¼ 200) 5 8(29.00) 70 (35.00) 72 (36.00) 186 (46.50) 214 (53.50)
ORa NASH 1.00 6.7772* 6.4729* 1.00 4.4618*
95% CI NASH 3.4196e10.2115 3.1795e10.2181 2.3782e8.1506
p NASH 0.0071 0.0075 0.0081
NAFHC (n ¼ 200) 22 (11.00) 87 (43.50) 91(45.50) 131 (32.75) 269 (67.25)
ORa NAFHC 1.00 22.2063*
,** 21.5682*,** 1.00 7.9633*,**
95% CI NAFHC 12.2647e29.3264 12.2657e31.1237 4.3706e9.1724
p NAFHC 0.0047 0.0045 0.0063
* Compared with ORa NAFL, p < 0.01.
** Compared with ORa NASH, p < 0.01.
CI ¼ confidence interval; NAFHC ¼ nonalcoholic fatty hepatic cirrhosis; NAFL ¼ nonalcoholic simple fatty liver; NASG ¼ nonalcoholic steatohepatitis;
OR ¼ odds ratio; SI ¼ smoking index.
a Adjusted according to sex, age, body mass index, waist circumference, hip circumference, waist-to-hip ratio, systolic blood pressure, diastolic blood pressure,
fasting blood glucose, aspartate transaminase, alanine transaminase, triglyceride, total cholesterol, low density lipoprotein cholesterol, fasting serum insulin, and
high sensitivity C-reactive protein, and smoking status.
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ORe1g1 > ORe1  ORg1, showing a super-multiplicative
model, and statistical analysis also suggested positive in-
teractions between SI  400 and -11377C/G (GG), SI > 400
and -11377C/G (CG), and SI > 400 and -11377C/G (GG) in
increasing the risk of NAFLD (g > 1; Table 6). Similarly,
there were also positive associations between SI  400 and
C594T (CT), SI  400 and C594T (TT), SI > 400 and C594T
(CT), and SI > 400 and C594T (TT) in increasing the risk of
NAFLD (g > 1; Table 7).
4. Discussion
Adiponectin has been identified as one of the most abun-
dant adipose-specific adipokines and plays a critical role in the
maintenance of insulin sensitivity and inhibiting liver fat
deposition.10 The expression of adiponectin is controlled by
genes and induced by environmental factors, and its inducible
expression levels exhibit individual differences. The human
adiponectin gene is located on chromosome 3q27, containing
three exons and two introns, encoding 244 amino acids. There
are a variety of single-nucleotide polymorphisms in the adi-
ponectin gene, such as -11377C/G, þ276G/T, and þ45T/G.
The -11377C/G polymorphism is considered the main mean-
ingful polymorphism in the adiponectin gene, affecting the
activity of the promoter and decreasing the expression of
adiponectin in blood and tissues, thereby affecting its bio-
logical effect. The adiponectin gene -11377C/G poly-
morphism has three genotypes, namely -11377C/G (CC),
-11377C/G (CG), and -11377C/G (GG). Studies have sug-
gested a correlation between the -11377C/G polymorphism
and metabolic syndrome.11,12 This study found that the risk of
NAFLD significantly increased in patients with the -11377C/G(CG) genotype (ORNAFL ¼ 2.5278; ORNASH ¼ 6.1823;
ORNAFHC ¼ 17.8570), and in those with the -11377C/G (GG)
genotype (ORNAFL ¼ 2.5900; ORNASH ¼ 6.4017;
ORNAFHC ¼ 18.9023). The mechanism of the -11377C/G
(GG) genotype being susceptible to NAFLD is not clear; a
related study showed that the G allele may decrease the
expression of adiponectin through inactivating adiponectin
gene transcription, thus decreasing insulin sensitivity,13 and
finally causing lipid deposition in the liver, raising the risk of
NAFLD.
GPx, an enzyme dependent on the micronutrient selenium,
plays a critical role in the reduction of lipid and hydrogen
peroxide. There are four subspecies of GPx that catalyze the
reduction of hydrogen peroxide in specific tissue locations.
GPx-1 is ubiquitous and found in the cytosol of most cells,
including red blood cells. GPx-2 is also cytosolic but is
confined to the gastrointestinal tract. GPx-3 occurs in plasma
as a glycoprotein, and GPx-4 interacts with complex lipids,
such as cholesterol and lipoproteins damaged by free radicals,
and is found in mitochondria.14 Human GPx-1 gene is located
on chromosome 3p21.3, containing two exons and one intron.
GPx-1 gene C594T polymorphism (rsl050450), which resides
in the coding region and results in an amino acid substitution
of proline with leucine (Pro198Leu), was reported to be
associated with a reduction of GPx-1 activity.15 Studies have
shown that GPx-1 gene C594T polymorphism may increase
the incidence of oxidative stress-related diseases such as
prostate cancer and bladder cancer.16,17 This study found that
the frequencies of C594T (CT) and C594T (TT) genotype in
the NAFL, NASH, and NAFHC groups were significantly
higher than that in control group (all p < 0.01), and the risk of
NAFLD significantly increased in patients with C594T (CT)
genotype (ORNAFL ¼ 2.6687; ORNASH ¼ 6.7772;
Table 5
Interaction of polymorphisms of adiponectin gene promoter -11377C/G and GPx-1 gene C594T in nonalcoholic fatty liver disease [n (%)].
Groups Combined genotypes of -11377C/G and C594T, n (%)]
CC/CC CC/CT CC/TT CG/CC CG/CT CG/TT GG/CC GG/CT GG/TT
Control (n ¼ 200) 104 (52.00) 19 (9.50) 20 (10.00) 20 (10.00) 4 (2.00) 4 (2.00) 22 (11.00) 3 (1.50) 4 (2.00)
NAFL (n ¼ 200) 50 (25.00) 24 (12.00) 25 (12.50) 25 (12.50) 12 (6.00) 12 (6.00) 26 (13.00) 12 (6.00) 14 (7.00)
ORa NAFL 1.00 2.6274
b(OR1) 2.6000
c(OR2) 2.6000
d(OR3) 6.2400
e(OR1*3) 6.2400
f(OR2*3) 2.4582
g(OR4) 8.3200
h(OR1*4) 7.2800
i(OR2*4)
95% CINAFL 1.3372e4.2108 1.2374e5.2183 1.2374e5.2183 3.9017e9.8561 3.9017e9.8561 1.0374e5.2516 5.0376e11.2487 4.0349e11.2124
bNAFL 0.4195(b1) 0.4150(b2) 0.4150(b3) 0.7959(b1*3) 0.7959(b2*3) 0.3906(b4) 0.9201(b1*4) 0.8621(b2*4)
NASH (n ¼ 200) 17 (8.50) 20 (10.00) 20 (10.00) 20 (10.00) 24 (12.00) 25 (12.50) 21 (10.50) 26 (13.00) 27 (13.50)
ORa NASH 1.00 6.4396
b(OR1)* 6.1176
c(OR2)* 6.1176
d(OR3)* 36.7059
e(OR1*3)* 38.2343
f(OR2*3)* 5.8396
g(OR4)* 53.0191
h(OR1*4)* 41.2941i(OR2*4)*
95% CINASH 3.4274e10.2195 3.3418e9.9047 3.0725e9.2172 25.7906e43.9718 26.0307e45.3295 2.6086e9.7419 32.6529e76.8971 28.0369e65.2114
b NASH 0.8089(b1)* 0.7866(b2)* 0.7866(b3)* 1.5647(b1*3)* 1.5824(b2*3)* 0.7664(b4)* 1.7244b1*4)* 1.6159(b2*4)*
NAFHC(n ¼ 200) 3 (1.50) 10 (5.00) 11 (5.50) 9 (4.50) 37 (18.50) 38 (19.00) 10 (5.00) 40 (20.00) 42 (21.00)
ORa NAFHC 1.00 18.2456
b(OR1)*
,** 19.0667c(OR2)*
,** 15.6000d(OR3)*
,** 320.6667e(OR1*3)*
,** 329.3333f(OR2*3)*
,** 15.7576g(OR4)*
,** 462.2219h(OR1*4)*
,** 363.9724i(OR2*4)*
,**
95% CINAFHC 11.2610e27.5473 11.7805e31.2596 9.0328e23.8758 270.3032e417.1824 282.1474e425.2187 9.0392e25.2471 398.5173e563.2182 297.0388e465.4694
b NAFHC 1.2611(b1)*
,** 1.2803(b2)*,** 1.1931(b3)*
,** 2.5061(b1*3)*
,** 2.5176(b2*3)*
,** 1.1975(b4)*
,** 2.6649(b1*4)*
,** 2.5611(b2*4)*
,**
* Compared with ORa NAFL, p < 0.01.
** Compared with ORa NASH, p < 0.01.
CI ¼ confidence interval; NAFHC ¼ nonalcoholic fatty hepatic cirrhosis; NAFL ¼ nonalcoholic simple fatty liver; NASG ¼ nonalcoholic steatohepatitis; OR ¼ odds ratio.
a Adjusted according to sex, age, body mass index, waist circumference, hip circumference, waist-to-hip ratio, systolic blood pressure, diastolic blood pressure, fasting blood glucose, aspartate transaminase,
alanine transaminase, triglyceride, total cholesterol, low density lipoprotein cholesterol, fasting serum insulin, and high sensitivity C-reactive protein, and smoking status.
b OR value by simple GPx-1-C594T heterozygote exposure (OR1).
c OR value by simple GPx-1-C594T homozygous mutant exposure (OR2).
d OR value by simple -11377C/G heterozygote exposure (OR3).
e OR value by the interaction of GPx-1-C594T heterozygote and -11377C/G heterozygote (OR1*3).
f OR value by the interaction of GPx-1-C594T homozygous mutant and -11377C/G heterozygote (OR2*3).
g OR value by simple -11377C/G homozygous mutant exposure (OR4).
h OR value by the interaction of GPx-1-C594T heterozygote and -11377C/G homozygous mutant (OR1*4).
i OR value by the interaction of GPx-1-C594T homozygous mutants and -11377C/G homozygous mutants (OR2*4).
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Table 6
Interaction of -11377C/G polymorphism of adiponectin gene promoter and cigarette smoking in nonalcoholic fatty liver disease [n (%)].
Groups 11377C/G genotype and smoking status, n (%)
CCþ
nonsmoking
CCþ
SI  400
CCþ
SI > 400
CGþ
nonsmoking
CGþ
SI  400
CGþ
SI > 4 00
GGþ
nonsmoking
GGþ
SI  400
GGþ
SI > 400
Control (n ¼ 200) 104 (52.00) 22 (11.00) 17 (8.50) 21 (10.50) 4 (2.00) 3 (1.50) 20 (10.00) 5 (2.50) 4 (2.00)
NAFL (n ¼ 200) 49 (24.50) 23 (11.50) 27 (13.50) 25 (12.50) 11 (5.50) 13 (6.50) 28 (14.00) 11 (5.50) 13 (6.50)
ORa NAFL 1.00 2.2189
b(ORe1) 3.3710
c(ORe2) 2.5267
d(ORg1) 5.8367
e(ORe1*g1) 9.1973
f(ORe2*g1) 2.9714
g(ORg2) 4.6694
h(ORe1*g2) 6.8980
i(ORe2*g2)
95% CINAFL 1.1347e4.8873 2.1075e5.8338 1.1374e5.1646 3.1385e9.2760 6.6540e11.2760 1.2974e5.9502 2.5975e9.0752 3.5076e10.5825
bNAFL 0.3461(be1) 0.5278(be2) 0.4026(bg1) 0.7662(ORe1*g1) 0.9637(be2*g1) 0.4730(bg2) 0.6693(be1*g2) 0.8387(be2*g2)
NASH (n ¼ 200) 17(8.50) 17 (8.50) 23 (11.50) 21 (10.50) 20 (10.00) 28 (14.00) 23 (11.50) 21 (10.50) 30 (15.00)
ORa NASH 1.00 4.7273
b(ORe1)* 8.2768
c(ORe2)* 6.1176
d(ORg1)* 30.5882
e(ORe1*g1)* 57.0980
f(ORe2*g1)* 7.0353g(ORg2)* 25.6941
h(ORe1*g2)* 45.8824
i(ORe2*g2)*
95% CINASH 2.1984e7.5307 4.8470e11.6043 4.5095e9.0598 19.3982e43.7804 42.8375e75.8043 3.6937e10.4085 16.0491e37.0938 34.8027e65.5538
b NASH 0.6746(be1)* 0.9179(be2)* 0.7866(bg1)* 1.4856(ORe1*g1)* 1.7566(be2*g1)* 0.8473(bg2)* 1.4098(be1*g2)* 1.6616(be2*g2)*
NAFHC (n ¼ 200) 3 (1.50) 8 (4.00) 13 (6.50) 12 (6.00) 29 (14.50) 43 (2150) 14 (7.00) 31 (15.50) 47 (23.50)
ORa NAFHC 1.00 12.6061
b(ORe1)*
,** 26.5098c(ORe2)*
,** 19.8095d(ORg1)*
,** 251.3332e(ORe1*g1)*
,** 496.8889f(ORe2*g1)*
,** 24.2667g(ORg2)*
,** 214.9333h(ORe1*g2)*
,** 407.3332i(ORe2*g2)*
,**
95% CI NAFHC 8.0724e19.5573 17.2628e32.4241 12.4194e25.9582 197.4072e375.9306 368.8164e579.0725 16.7806e35.2714 156.7430e2895.0426 362.6923e475.3762
b NAFHC 1.1006(be1)*
,** 1.42324(be2)*
,** 1.2969(bg1)*
,** 2.4002(ORe1*g1)*
,** 2.6963(be2*g1)*
,** 1.3850(bg2)*
,** 2.3323(be1*g2)*
,** 2.6099(be2*g2)*
,**
* Compared with ORa NAFL, p < 0.01.
** Compared with ORa NASH, p < 0.01.
CI ¼ confidence interval; NAFHC ¼ nonalcoholic fatty hepatic cirrhosis; NAFL ¼ nonalcoholic simple fatty liver; NASG ¼ nonalcoholic steatohepatitis; OR ¼ odds ratio; SI ¼ smoking index.
a Adjusted according to sex, age, body mass index, waist circumference, hip circumference, waist-to-hip ratio, systolic blood pressure, diastolic blood pressure, fasting blood glucose, aspartate transaminase, alanine
transaminase, triglyceride, total cholesterol, low density lipoprotein cholesterol, fasting serum insulin, and high sensitivity C-reactive protein.
b OR value by simple SI  400 exposure (ORe1).
c OR value by simple SI > 400 exposure (ORe2).
d OR value by simple heterozygote type exposure (ORg1).
e OR value by the interaction of SI  400 and heterozygote (ORe1g1).
f OR value by the interaction of SI > 400 and heterozygote (ORe2g1).
g OR value by simple homozygous mutant type exposure (ORg2).
h OR value by the interaction of SI  400 and homozygous mutant (ORe1g2).
i OR value by the interaction of SI > 400 and homozygous mutant (ORe2g2).
Table 7
Interaction of GPx-1 gene C594T polymorphism and cigarette smoking in nonalcoholic fatty liver disease [n (%)].
Groups C594T genotype and smoking status, n (%)
CCþ
nonsmoking
CCþ
SI  400
CCþ
SI > 400
CTþ
nonsmoking
CTþ
SI  400
CTþ
SI > 400
TTþ
non-smoking
TTþ
SI  400
TTþ
SI > 400
Control (n ¼ 200) 106 (53.00) 23 (11.50) 17 (8.50) 19 (9.50) 4 (2.00) 3 (1.50) 20 (10.00) 4 (2.00) 4 (2.00)
NAFL (n ¼ 200) 51 (25.50) 23 (11.50) 27 (13.50) 24 (12.00) 11 (5.50) 13 (6.50) 27 (13.50) 11 (5.50) 13 (6.50)
ORa NAFL 1.00 2.0784
b(ORe1) 3.3010
c(ORe2) 2.6254
d(ORg1) 5.7157
e(ORe1*g1) 9.0065
f(ORe2*g1) 2.8059
g(ORg2) 5.7157
h(ORe1*g2) 6.7549
i(ORe2*g2)
95% CI NAFL 1.2165e3.4716 1.8975e5.4706 1.8794e5.4036 3.2059e8.8945 6.9137e12.5496 1.4649e5.2871 3.7930e8.5063 3.9592e9.5945
bNAFL 0.3177(be1) 0.5186(be2) 0.4192(bg1) 0.7571(ORe1*g1) 0.9546(be2*g1) 0.4481(bg2) 0.7571(be1*g2) 0.8296(be2*g2)
NASH (n ¼ 200) 18 (9.00) 17 (8.50) 23 (11.50) 21 (10.50) 20 (10.00) 29 (14.50) 22 (11.00) 21 (10.50) 29 (14.50)
ORa NASH 1.00 4.3527
b(ORe1)* 7.9673
c(ORe2)* 6.5088
d(ORg1)* 29.4444
e(ORe1*g1)* 56.9260
f(ORe2*g1)* 6.4778
g(ORg2)* 30.9167
h(ORe1*g2)* 42.6944
i(ORe2*g2)*
95% CI NASH 2.5725e7.1792 4.7594e11.9703 3.2926e10.4238 17.5902e41.9794 41.6439e75.5394 3.2375e9.2084 21.6724e45.2871 29.6598e55.2037
b NASH 0.6388(be1)* 0.9013(be2)* 0.8135(bg1)* 1.4690(ORe1*g1)* 1.7553(be2*g1)* 0.8114(bg2)* 1.4902(be1*g2)* 1.6304(be2*g2)*
NAFHC (n ¼ 200) 3 (1.50) 7 (3.50) 12 (6.00) 12 (6.00) 30 (15.00) 45 (22.50) 14 (7.00) 31 (15.50) 46 (23.00)
ORa NAFHC 1.00 10.7536
b(ORe1)*
,** 24.9412c(ORe2)*
,** 22.3158d(ORg1)*
,** 265.0000e(ORe1*g1)*
,** 529.7583f(ORe2*g1)*
,** 24.7333g(ORg2)*
,** 273.8279h(ORe1*g2)*
,** 406.3297i(ORe2*g2)*
,**
95% CI NAFHC 6.5913e17.8692 17.6328e35.8407 16.7291e33.4827 198.6917e305.9704 432.6493e652.8715 15.6108e32.5838 194.3328e365.2179 327.3965e513.0576
b NAFHC 1.0316(be1)*
,** 1.3969(be2)*
,** 1.3486(bg1)*
,** 2.4232(ORe1*g1)*
,** 2.7241(be2*g1)*
,**) 1.3933(bg2)*
,** 2.4375(be1*g2)*
,** 2.6089(be2*g2)*
,**
* Compared with ORa NAFL, p < 0.01.
** Compared with ORa NASH, p < 0.01.
CI ¼ confidence interval; NAFHC ¼ nonalcoholic fatty hepatic cirrhosis; NAFL ¼ nonalcoholic simple fatty liver; NASG ¼ nonalcoholic steatohepatitis; OR ¼ odds ratio; SI ¼ smoking index.
b OR value by simple SI  400 exposure (ORe1).
c OR value by simple SI > 400 exposure (ORe2).
d OR value by simple heterozygote type exposure (ORg1).
e OR value by the interaction of SI  400 and heterozygote (ORe1g1).
f OR value by the interaction of SI > 400 and heterozygote (ORe2g1).
g OR value by simple homozygous mutant type exposure (ORg2).
h OR value by the interaction of SI  400 and homozygous mutant (ORe1g2).
i OR value by the interaction of SI > 400 and homozygous mutant (ORe2g2).
a Adjusted according to sex, age, body mass index, waist circumference, hip circumference, waist-to-hip ratio, systolic blood pressure, diastolic blood pressure, fasting blood glucose, aspartate transaminase, alanine
transaminase, triglyceride, total cholesterol, low density lipoprotein cholesterol, fasting serum insulin, and high sensitivity C-reactive protein.
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(ORNAFL ¼ 2.6330; ORNASH ¼ 6.4729; ORNAFHC ¼ 21.5682),
which corresponded with the results of other related
researches.
This study found that the interaction of -11377C/G and
GPx-1 gene C594T mutation increased the risk for NAFLD.
The -11377C/G (GG) and C594T (TT) genotypes in NAFLD
had super-multiplicative effect (g2NAFL ¼ 2.2071, g4
NAFL ¼ 2.0773; g2NASH ¼ 2.1084, g4NASH ¼ 2.0543; g2
NAFHC ¼ 2.1387, g4NAFHC ¼ 2.0004). Likewise, there were
also positive interactions in the pathogenesis of NAFLD be-
tween -11377C/G (CG) and C594T (TT), -11377C/G (CG)
and C594T (CT), and -11377C/G (GG) and C594T (CT). The
risk of NAFLD significantly increased in individuals with
SI  400 (ORNAFL ¼ 2.0636; ORNASH ¼ 4.4474;
ORNAFHC ¼ 10.9677) and in those with SI > 400
(ORNAFL ¼ 3.1393; ORNASH ¼ 8.0225;
ORNAFHC ¼ 21.4583), and statistical analysis suggested
positive interactions between cigarette smoking and -11377C/
G (CG), -11377C/G (GG), C594T(CT), and C594T (TT) in
increasing the risk of NAFLD (all g > 1). The OReg of each of
the two genotypes and smoking exposure was greater than
ORe  ORg, indicating that the two homozygous mutant
genes and smoking interact in a supermultiplicative manner in
the pathogenesis of NAFLD. Long-term smoking can cause
oxidation of glucose metabolism in cells, significantly
weaken nonoxidative pathways, and increase free fatty acids
levels in plasma, and which can be taken up by liver and
adipose tissue and synthesize triglycerides, leading to the
development of insulin resistance. The nicotine in tobacco can
cause sympathetic excitement, leading to an increased release
of catecholamines and glucagon, which are potent antagonists
of insulin action. The impaired insulin action creates the
conditions for the first hit in the pathogenesis of NAFLD.18,19
Usually, the body can clean out excess free radicals thanks to
the existence of the free radical scavenging system including
GPx-1, while a variety of compounds in cigarettes can in-
crease the levels of harmful free radicals. In the bodies of
long-term smokers, excessive oxidizing free radicals travel
through the blood into the liver cells, inducing lipid peroxi-
dation and free radical reaction, and eventually leading to
fatty liver. This may be the reason why smoking can promote
the risk of NAFLD by -11377C/G (CG), -11377C/G (GG),
C594T (CT), and C594T (TT).
NAFLD is a complex process involving interaction of
environmental factors and multiple genes. This study suggests
that carriers of adiponectin gene promoter-11377C/G (CG),
-11377C/G (GG), and GPx-1 gene C594T (CT) and C594T
(TT) genotypes may have a high risk of NAFLD, and the gene
genotypes can interact with cigarette smoking in the patho-
genesis of NAFLD. In order to achieve effective prevention of
NAFLD, measures controlling environmental factors, such as
smoking cessation, need to be taken.References
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